

# Le esperienze internazionali di adesione al test HPV e ai protocolli

Guglielmo Ronco  
CPO Piemonte - Torino

**GISCI**

*Gruppo Italiano Screening del Cervicocarcinoma*

## **CONVEGNO NAZIONALE 2013**

***LO SCREENING CERVICALE TRA PRESENTE E FUTURO  
ACCOMPAGNARE IL CAMBIAMENTO***

23-24 Maggio 2013


# **Dati dalle survey dei progetti pilota**

***Manuel Zorzi***

***Registro Tumori del Veneto***

# **ADESIONE ALL'INVITO**

# Programmi pilota con test HPV primario



# Compliance to invitation by arm

## Finnish trial


	HPV screening arm	Conventional screening arm
All ages	66410/101678 65.3%	65784/101747 64.7%
25-34	11191/20460 54.7%	11071/20455 54.1%
35-65	55219/81218 68.0%	54713/81292 67.3%

**Table 2| Hazard ratios of invasive cervical cancer (ICC), AIS, or CIN among women invited for organised cervical screening in Finland, by screening status**

	No of cases detected in women aged 25-34 years		No of cases detected in women aged ≥35 years		Hazard ratio (95% CI)		
	HPV screening arm	Conventional screening arm	HPV screening arm	Conventional screening arm	Age 25-34 years	Age ≥35 years	Overall
<b>All women invited</b>							
ICC	1	6	24	25	0.17 (0.02 to 1.39)	0.96 (0.55 to 1.68)	0.81 (0.48 to 1.37)
CIN 3 or AIS	90	70	158	119	1.29 (0.95 to 1.77)	1.33 (1.05 to 1.69)	1.32 (1.09 to 1.59)
CIN 2	209	135	236	155	1.56 (1.25 to 1.93)	1.53 (1.25 to 1.87)	1.54 (1.33 to 1.78)
CIN 1	117	68	175	123	1.73 (1.28 to 2.33)	1.43 (1.13 to 1.80)	1.53 (1.28 to 1.84)
<b>Women who attended</b>							
ICC	1	2	16	7	0.49 (0.04 to 5.42)	2.27 (0.93 to 5.51)	1.87 (0.83 to 4.20)
CIN 3 or AIS	62	32	116	77	1.92 (1.25 to 2.94)	1.50 (1.12 to 2.00)	1.62 (1.28 to 2.06)
CIN 2	155	85	190	116	1.81 (1.39 to 2.35)	1.63 (1.29 to 2.05)	1.71 (1.43 to 2.03)
CIN 1	88	43	138	84	2.03 (1.41 to 2.92)	1.63 (1.25 to 2.14)	1.77 (1.42 to 2.20)
<b>Women who did not attend</b>							
ICC	0	4	8	18	NA	0.45 (0.20 to 1.04)	0.37 (0.17 to 0.83)
CIN 3 or AIS	28	38	42	42	0.75 (0.46 to 1.23)	1.02 (0.66 to 1.56)	0.89 (0.65 to 1.23)
CIN 2	54	50	46	39	1.10 (0.75 to 1.62)	1.20 (0.78 to 1.84)	1.15 (0.86 to 1.52)
CIN 1	29	25	37	39	1.19 (0.69 to 2.02)	0.97 (0.62 to 1.52)	1.05 (0.75 to 1.48)

NA=not applicable. Association between age and ICC was not significant (P=0.83 among all invited, P=0.96 among women who attended, and P=0.12 among women who did not attend). Associations between age and CIN 1, CIN 2, and CIN 3 or AIS were significant (P<0.001 among all subgroups of attendance). There was significant effect modification between age and screening method only for CIN 1 among all women invited (P=0.002) and among women who attended (P=0.004).

# Programmi pilota con test HPV primario




Programma	Campagna promozionale	Invito
Abruzzo	<b>Nessuna</b>	Lettera + depliant informativo
Guidonia	Solo primo round: campagne informative a livello comunale	Lettera + depliant informativo
Reggio Emilia	Su televisioni e su giornali locali	Lettera + depliant informativo
Torino	<b>Nessuna</b>	Lettera + depliant informativo
Trento	Iniziative nell'ambito del programma di aggiornamento sugli screening	Lettera + depliant informativo
Umbria	Campagna di promozione	Lettera + depliant informativo
Valcamonica		
Alta padova	Comunicazione a operatori (MMG, ginecologi)	Lettera + depliant informativo
Padova	Manifesti in consultori, studi MMG, farmacie	Lettera + depliant informativo
Este	Articolo su giornale locale Campagna di promozione in seconda fase	Lettera + depliant informativo
Rovigo	Articolo su giornale locale	Lettera + depliant informativo
Adria	<b>Nessuna</b>	Lettera + depliant informativo



# Adesione all'invito

## Survey su attività 2011



# Pilot project design

- Centres: Torino, Trento & Reggio Emilia
- Cluster randomised (birth cohort) to HPV or cytology
- Age 35-64

# Torino, Reggio Emilia e Trento: adesione all'invito

Centro	Invitate HPV	Aderenti HPV	Invitate citologia	Aderenti citologia	RR (95%CI)
Torino	66930	34209 (51.1%)	56666	28264 (49.9%)	1.02 (1.01-1.04)
Reggio Emilia	19826	11959 (60.3%)	17935	10554 (58.9%)	1.05 (1.03-1.07)
Trento	10748	6109 (56.8%)	8571	5928 (69.2%)	0.82 (0.80-0.84)
Totale	97504	52277 (53.6%)	83172	44746 (53.8%)	1.01 (0.99-1.03)*

\* standardizzato per centro


# Randomised Pilot Project Italy

## Compliance to invitation


women invited within may 2012

<b>Centre</b>	<b>Invited HPV</b>	<b>Compliance HPV</b>	<b>Invited cytology</b>	<b>Compliance cytology</b>	<b>RR (95%CI)</b>
<b>Torino</b>	54123	27683 <b>(51.1%)</b>	45283	22751 <b>(50.2%)</b>	<b>1.03</b> (1.01-1.04)
<b>Reggio Emilia</b>	16825	11678 <b>(69.4%)</b>	15338	9233 <b>(60.2%)</b>	<b>1.15</b> (1.13-1.17)
<b>Total</b>	70948	39361 <b>(55.5%)</b>	60621	31984 <b>(52.8%)</b>	<b>1.05</b> (1.06-1.06)


# Adesione all'invito ai programmi pilota con HPV




# Adesione: HPV vs Pap



# VENETO - Adesione corretta all'invito




# VENETO - Adesione corretta all'invito, per età






## UMBRIA - Adesione all'invito per età




# UMBRIA - Il peso dei solleciti

età	quota sollecitate	adesione senza sollecito
HPV	41,6	51,9
PAP	88,2	44,2


## UMBRIA - Adesione all'invito per età, esclusi i solleciti




# ABRUZZO - Adesione all'invito per anno



# GUIDONIA - Adesione all'invito per ROUND



## ESTE - Adesione corretta all'invito (%)




# Relative positive predictive value for CIN2+ and CIN3+ at 1° round of HPV-based vs. cytology-based screening according to the screening policy with HPV

	Co-testing			Stand alone HPV		
	Study	CIN2+	CIN3+	Study	CIN2+	CIN3+
Triage	<b>POBASCAM</b>	0.95	1.03	<b>Finnish</b>	1.34 (1.04 - 1.72)	1.22 (0.78 - 1.92).
	<b>ARTISTIC</b>	0.98	1.15			
	<b>NTCC PH1 age 25-34</b>	0.55 (0.37-0.82)	0.24 (0.13-0.45)			
Direct referral	<b>NTCC PH1 age 25-34</b>	0.40 (0.23-0.66)	0.34 (0.21-0.54)	<b>NTCC PH2 age 25-34</b>	0.89 (0.55-1.44)	0.66 (0.31-1.40)
				<b>NTCC PH2 age 25-34</b>	0.80 (0.55-1.18)	0.86 (0.49-1.52)

# Studio POBASCAM

## Gestione donne HPV+ citologia normale



Donne 29-56

**Compliance**

**Prima ripetizione: 82% (376/459)**

**Entrambe le ripetizioni: 58%  
(268/459)**

Bulkmans, Lancet 2007



# Swedescreen trial – compliance to protocol

## PROTOCOL:

If HPV+ and Pap- repeat HPV test after 12 months

If persistent type-specific infection referred to colposcopy.

Offered second HPV test	341	100%	
Had second HPV test	270	79.2%	
Had persistent type-specific HPV infection	119	34.9%	100%
Had colposcopy	100	29.3%	84.0%

# NTCC trial phase 1 women age 25.34 yrs compliance to protocol

## PROTOCOL:


If HPV+ and had normal cytology repeat HPV test and cytology after 12 months

If persistent HPV or cytology ASCUS+ referred to colposcopy.


Were HPV+ and had normal cytology	510	100%	
Had immediate colposcopy	14	2.7%	
Had second HPV and cytology test	339	66.5%	
Had persistent HPV infection or cytology ASCUS+	164	32.2%	100%
Had colposcopy	148	29.0%	90.2%



# Artistic study

## Clinical management and timelines according to cytology grade in screening round 1 and by study group




# ARTISTIC trial Compliance to triage





Arbyn et al, Vaccine 2012

# HPV- vs cytology based screening CIN3+ in 2<sup>nd</sup> round



<b>Programma</b>	<b>Richiamo a 12 mesi</b>
Abruzzo	<b>Lettera</b>
Guidonia	Prima fase: telefonata <b>Seconda fase: lettera</b> Attualmente telefonata
Reggio Emilia	Lettera + telefonata di sollecito (in seconda fase)
Torino	Lettera + telefonata di sollecito
Trento	<b>Lettera personalizzata</b>
Umbria	<b>Lettera</b>
Valcamonica	
Alta padova	<b>Lettera</b>
Padova	Lettera + telefonata di sollecito
Este	Lettera + telefonata di sollecito
Rovigo	Lettera + telefonata di sollecito
Adria	Lettera + telefonata di sollecito


# Torino, Reggio Emilia: adesione alla ripetizione a 12 mesi

Centre	HPV positive at baseline	Compliance test repeat 1 year	HPV positive at 1 year Test repeat
<b>Torino</b>	1448/2476 <b>5.9%</b> (5.6 - 6.2)	401/442 <b>90.7%</b> (87.6 - 93.3)	227/401 <b>56.6%</b> (51.5-61.5)
<b>Reggio Emilia</b>	445/10339 <b>4.3%</b> (3.9 - 4.7)	212/263 <b>80.6%</b> (75.3 - 85.2)	89/212 <b>42.0%</b> (35.3-49.0)
<b>Totale</b>	1893/35100 <b>5.4%</b> (5.2 - 5.6)	613/705 <b>87.0%</b> (84.5-89.4)	316/613 <b>51.5%</b> (47.6-55.5)

Lettera+telefonata sollecito




## VENETO - Ripetizione a 12 mesi: adesione all'invito, per programma




Lettera + telefonata sollecito

## VENETO - Adesione alla ripetizione a 12 mesi, per età



# VALCAMONICA - Adesione alla ripetizione a 1 anno




# UMBRIA

## RIPETIZIONE A 1 ANNO

**Dopo 1 anno** sono state richiamate  
telefonicamente 128 donne e sono tornate 90  
(70%)

# GUIDONIA - Adesione alla ripetizione a 12 mesi per modalità di invito




# ABRUZZO

## RIPETIZIONE A 1 ANNO

<i>1° round 2010</i>	<i>%</i>
567 / 1372	41,30%

Lettera

# Adesione alla ripetizione a 1 anno per programma



# Conclusioni

- Maggiore adesione rispetto al pap test in quasi tutti i contesti
- Molto variabile la compliance al richiamo ad 1 anno. Sollecito telefonico necessario
- Quale adesione al re-screening a 5 anni?